Melphalan-Hydrochloride

Drug Overview

Melphalan-Hydrochloride is a potent, bifunctional alkylating agent that has served as a cornerstone in the treatment of multiple myeloma and ovarian cancer for decades. Originally derived as a nitrogen mustard derivative of L-phenylalanine, it functions as a non-specific cytotoxic drug that targets rapidly dividing cells. While newer targeted therapies have emerged, Melphalan remains a critical component of high-dose conditioning regimens used prior to stem cell transplantation.

• Generic Name: Melphalan Hydrochloride
• US Brand Names: Alkeran®, Evomela® (Captisol-enabled formulation)
• Drug Class: Nitrogen Mustard Alkylating Agent
• Route of Administration: Intravenous (IV) Injection; Oral (Tablets)
• FDA Approval Status: Approved (First approved in 1964)

What Is It and How Does It Work? (Mechanism of Action)

Melphalan works by chemically altering the DNA of cancer cells, preventing them from replicating and surviving.

Molecular Mechanism:

1. Structure: Melphalan is a phenylalanine derivative of nitrogen mustard. The phenylalanine transporter on cell membranes actively transports the drug into cancer cells, which often have higher metabolic demands for amino acids.
2. Carbonium Ion Formation: Once inside the cell, Melphalan undergoes a chemical transformation to form highly reactive intermediate ions (carbonium ions).
3. DNA Alkylation: These reactive ions attack the nucleophilic centers of DNA bases, specifically the N-7 position of guanine.
4. Cross-Linking: The drug binds to two different DNA strands simultaneously (bifunctional alkylation), creating interstrand cross-links. These cross-links act like a padlock, preventing the DNA strands from separating during replication and transcription.
5. Apoptosis: The inability to replicate DNA or repair the damage leads to cell cycle arrest (typically in the G2/M phase) and triggers apoptosis (programmed cell death).

FDA Approved Clinical Indications

Melphalan is FDA-approved for the palliative treatment of specific malignancies.

Oncological Uses:

• Multiple Myeloma: Palliative treatment of multiple myeloma. Used for patients who are not candidates for transplant (oral/IV) or as a high-dose conditioning regimen prior to hematopoietic progenitor (stem) cell transplantation (Evomela® indication).
• Epithelial Ovarian Cancer: Palliative treatment of non-resectable epithelial carcinoma of the ovary.

Non-Oncological Uses:

• There are currently no FDA-approved non-oncological indications for Melphalan.

Dosage and Administration Protocols

Dosing varies significantly depending on whether the drug is used for standard palliative care or as high-dose conditioning for stem cell transplant.

Standard Dosing Regimen

Dose Adjustments:

• Renal Impairment:
  • Oral: Reduce dose by 50% if BUN > 30 mg/dL.
  • IV: Reduce dose by 50% if Creatinine Clearance (CrCl) < 30-40 mL/min to avoid severe bone marrow suppression.
• Bone Marrow Suppression: Discontinue temporarily if WBC < 3,000/mm³ or Platelets < 100,000/mm³. Resume at a lower dose upon recovery.

Clinical Efficacy and Research Results

Melphalan remains the gold standard for conditioning regimens in autologous stem cell transplantation (ASCT) for Multiple Myeloma, despite being an older drug.

• High-Dose Melphalan (HDM) in Myeloma:
  • Current data (2020-2024) consistently reinforces that high-dose Melphalan (200 mg/m²) followed by ASCT provides deeper responses and longer Progression-Free Survival (PFS) compared to standard chemotherapy alone in eligible patients.
  • Median PFS for patients receiving HDM + ASCT is approximately 45–60 months in the era of novel induction therapies (like VRd or D-VRd).
• Evomela® (Propylene Glycol-Free):
  • The reformulated Captisol-enabled Melphalan (Evomela) has shown bioequivalence to standard Melphalan but with better stability (allowing longer infusion times of 30 mins vs 15 mins) and potentially lower rates of mucositis.
• AL Amyloidosis: While off-label in some regions, Melphalan combined with Dexamethasone remains a highly effective regimen for AL Amyloidosis, with hematologic response rates exceeding 60-70% in selected patients.

Safety Profile and Side Effects

BLACK BOX WARNINGS

• Severe Bone Marrow Suppression: Leukopenia, thrombocytopenia, and anemia. Infections and bleeding can be fatal.
• Hypersensitivity: Severe anaphylactic reactions can occur (approx. 2% of patients).
• Secondary Malignancies: Melphalan is leukemogenic. Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) can develop months to years after treatment.
• Mutagenicity/Infertility: Melphalan causes chromosomal suppression and suppression of ovarian/testicular function.

Common Side Effects (>10%)

• Hematologic: Severe Myelosuppression (Neutropenia, Thrombocytopenia, Anemia). Nadir usually occurs 14–21 days after administration.
• Gastrointestinal: Nausea, vomiting, diarrhea, Mucositis/Stomatitis (mouth sores are very common with high doses).
• Dermatologic: Alopecia (hair loss), rash.
• Reproductive: Amenorrhea (cessation of periods), irreversible infertility.

Serious Adverse Events

• Pulmonary Fibrosis: Rare but potentially fatal lung scarring.
• Secondary Malignancies: Risk of secondary leukemia (AML/MDS) is significantly elevated compared to the general population.
• Veno-Occlusive Disease (VOD): Liver toxicity involving blockage of small liver veins, particularly in transplant settings.
• Cardiac Toxicity: Atrial fibrillation or cardiac arrest (rare, associated with high doses).

Management Strategies:

• Mucositis: Cryotherapy (chewing ice chips) during the infusion (specifically 30 mins before, during, and 30 mins after) significantly reduces the severity of mouth sores by constricting blood vessels in the mouth.
• Nausea: Premedicate with 5-HT3 antagonists (ondansetron) and dexamethasone.
• Infection: Prophylactic antibiotics and G-CSF support are standard for high-dose regimens.

Connection to Stem Cell and Regenerative Medicine

Melphalan is intrinsically linked to Hematopoietic Stem Cell Transplantation (HSCT).

• Myeloablation: High-dose Melphalan is classified as a myeloablative agent. Its purpose in the transplant setting is to completely destroy the patient’s bone marrow (both healthy and cancerous cells). This creates physical space in the marrow and suppresses the immune system to prevent rejection.
• Stem Cell Rescue: Because the dose used is lethal to the bone marrow, the patient must receive an infusion of previously collected stem cells (Regenerative Medicine) 24 to 48 hours after the Melphalan clears the system. These stem cells migrate to the marrow cavities (homing) and regenerate the entire blood and immune system over the course of 10-20 days.
• Current Research: Studies are investigating combining Melphalan with novel agents (like targeted radiotherapies or immunotherapies) in the conditioning phase to kill resistant myeloma clones without increasing the toxicity to the regenerating stem cells.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Complete Blood Count (CBC): Mandatory to assess baseline marrow function.
• Renal Function: Serum Creatinine/BUN (vital for dose calculation).
• Pregnancy Test: Mandatory for females of reproductive potential.
• Dental Exam: Recommended before high-dose therapy to reduce infection risk during mucositis.

Precautions During Treatment:

• Cryotherapy: Patients receiving high-dose Melphalan should suck on ice chips during the infusion to prevent severe mouth sores.
• Hydration: Maintain aggressive hydration to prevent renal toxicity.

Do’s and Don’ts List:

• DO use effective contraception. Melphalan causes severe birth defects.
• DO bring a warm blanket to the infusion center; cryotherapy (ice chips) can make you feel cold.
• DO report any fever (>100.4°F) immediately; your immune system will be severely compromised.
• DON’T receive live vaccines (e.g., MMR, Varicella) during treatment.
• DON’T ignore bruising or bleeding gums; this indicates low platelets.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is intended for international patients and healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Melphalan Hydrochloride (Alkeran®, Evomela®) is a potent cytotoxic prescription medication; its use must be determined by a qualified hematologist or oncologist based on individual patient history and renal function. Dosing, protocols, and approval status may vary by country and regulatory jurisdiction. Always consult with a healthcare provider regarding specific medical conditions and treatment options.